These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 946307)

  • 1. Cardiovascular risk and use of estrogens or estrogen-progestagen combinations. Stanford three-community study.
    Stern MP; Brown BW; Haskell WL; Farquhar JW; Wehrle CL; Wood PD
    JAMA; 1976 Feb; 235(8):811-5. PubMed ID: 946307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
    Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
    J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral contraceptives and physiological variables.
    Ostrander LD; Lamphiear DE; Block WD; Williams GW; Carmen WJ
    JAMA; 1980 Aug; 244(7):677-9. PubMed ID: 6993716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogens and hypertension.
    Weinberger MH
    Compr Ther; 1982 Jun; 8(6):71-5. PubMed ID: 7105645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart disease risk factors and hormone use in postmenopausal women.
    Barrett-Connor E; Brown WV; Turner J; Austin M; Criqui MH
    JAMA; 1979 May; 241(20):2167-9. PubMed ID: 430817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum high-density-lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins.
    Bradley DD; Wingerd J; Petitti DB; Krauss RM; Ramcharan S
    N Engl J Med; 1978 Jul; 299(1):17-20. PubMed ID: 207983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population.
    Morin-Papunen L; Martikainen H; McCarthy MI; Franks S; Sovio U; Hartikainen AL; Ruokonen A; Leinonen M; Laitinen J; Järvelin MR; Pouta A
    Am J Obstet Gynecol; 2008 Nov; 199(5):529.e1-529.e10. PubMed ID: 18533124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complications of oral contraceptive agents-a symposium. Effects of oral contraceptives on carbohydrate metabolism.
    Bray GA
    West J Med; 1975 Jan; 122(1):33-5. PubMed ID: 1089004
    [No Abstract]   [Full Text] [Related]  

  • 11. The Royal College of General Practitioners' Oral Contraception Study: some recent observations.
    Kay CR
    Clin Obstet Gynaecol; 1984 Dec; 11(3):759-86. PubMed ID: 6509858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of oral contraceptives and obesity on protein C antigen.
    Meade TW; Stirling Y; Wilkes H; Mannucci PM
    Thromb Haemost; 1985 Apr; 53(2):198-9. PubMed ID: 3839605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral contraceptives and blood pressure.
    Fisch IR; Frank J
    JAMA; 1977 Jun; 237(23):2499-503. PubMed ID: 576962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen, progestogens and cardiovascular risk.
    Stefanick ML
    J Reprod Med; 1999 Feb; 44(2 Suppl):221-6. PubMed ID: 11392036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Myocardial infarct and ovulation inhibitors].
    Zimmermann KG; Siegenthaler W
    Dtsch Med Wochenschr; 1975 Jun; 100(26):1441-3. PubMed ID: 1149628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of hyperlipidemia in women and its association with use of oral contraceptives, sex hormone replacement therapy and nonlipid coronary artery disease risk factors. Canadian Heart Health Surveys Research Group.
    Connelly PW; Stachenko S; MacLean DR; Petrasovits A; Little JA
    Can J Cardiol; 1999 Apr; 15(4):419-27. PubMed ID: 10322251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The correlation of blood pressure, cholesterol and triglyceride concentration with the administration of hormonal contraceptives in women from 2 Erfurt large-scale plants].
    Heinrich J; Knappe J; Gräfner L; Holtz H; Rühling K; Schauer I; Dück KD; Strube G
    Z Gesamte Inn Med; 1979 Sep; 34(18):540-4. PubMed ID: 516840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pill formulations and their effect on lipid and carbohydrate metabolism.
    Brooks PG
    J Reprod Med; 1984 Jul; 29(7 Suppl):539-46. PubMed ID: 6481707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.